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Abstract The treatment of chronic pain is poorly managed by current analgesics, and there is a
need for new classes of drugs. We recently developed a series of bioactive lipids that inhibit the
human glycine transporter GlyT2 (SLC6A5) and provide analgesia in animal models of pain. Here,
we have used functional analysis of mutant transporters combined with molecular dynamics
simulations of lipid-transporter interactions to understand how these bioactive lipids interact with
GlyT2. This study identifies a novel extracellular allosteric modulator site formed by a crevice
between transmembrane domains 5, 7, and 8, and extracellular loop 4 of GlyT2. Knowledge of this
site could be exploited further in the development of drugs to treat pain, and to identify other
allosteric modulators of the SLC6 family of transporters.
DOI: https://doi.org/10.7554/eLife.47150.001
Introduction
Inhibitory glycinergic neurotransmission plays an important role in the spinal cord dorsal horn, regu-
lating excitatory tone in the ascending pain pathway to prevent excess nociceptive signalling
(Todd, 2010). Concentrations of glycine within the synapse are tightly controlled by two subtypes of
secondary active glycine transporters, GlyT1 (SLC6A9) and GlyT2 (SLC6A5) (Eulenburg et al., 2005).
GlyT1 is expressed throughout the central nervous system, while the expression of GlyT2 is localised
to presynaptic inhibitory neurons and allows for rapid removal of glycine from inhibitory synapses
and for recycling glycine into synaptic vesicles (Roux and Supplisson, 2000; Zafra et al., 1995). The
unique role of GlyT2 in pain processing has driven the development of a number of GlyT2 inhibitors
for the treatment of chronic pain (Caulfield et al., 2001; Takahashi et al., 2014; Vandenberg et al.,
2014; Xu et al., 2005). Inhibition of GlyT2 in this region should increase glycine concentrations
within the synapse, allow prolonged activation of glycine receptors, and reduce the firing of excit-
atory pain-projecting neurons (Cioffi, 2018).
We have previously developed a new class of GlyT2 inhibitors based on the structure of the
endogenous analgesic bioactive lipid, N-arachidonyl glycine (NAGly) (see Figure 1—figure supple-
ment 1 and Supplementary file 2 for representative structures) (Mostyn et al., 2017;
Mostyn et al., 2019). NAGly has a relatively low potency (IC509 mM) (Wiles et al., 2006), and using
a medicinal chemistry approach we prepared a number of synthetic acyl amino acids that inhibit
GlyT2 at concentrations in the low nanomolar range. Bioactive lipid inhibitors containing positively
charged amino acid head groups are the most potent followed by aromatic, aliphatic, polar, and
negatively charged amino acid head groups. One of these lipids, oleoyl D-lysine (ODLys), is potent,
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metabolically stable, blood brain barrier permeable, and produces analgesia in a rat model of neuro-
pathic pain with minimal side effects (Mostyn et al., 2019). In this study, we have investigated how
bioactive lipids bind and inhibit GlyT2, which will provide a structural framework for further design
of allosteric inhibitors of GlyT2 that could form part of long term treatment options for patients with
chronic pain.
Glycine transporters are members of the neurotransmitter sodium symporter (NSS) or SLC6 family
of transporters which are secondary active transporters that exploit the Na+ gradient to drive trans-
port of amino acids and amino acid derivatives across cell membranes (Kristensen et al., 2011).
Structures of the Drosophila dopamine transporter (dDAT) (Penmatsa et al., 2013; Penmatsa et al.,
2015; Wang et al., 2015), the human serotonin transporter (hSERT) (Coleman et al., 2016;
Coleman et al., 2019), and the bacterial leucine transporter (LeuT) (Krishnamurthy and Gouaux,
2012; Yamashita et al., 2005), suggest a common transport mechanism for the SLC6 family. Sub-
strate and co-transported ions enter the extracellular facing vestibule, followed by movements of
extracellular loop 4 (EL4) to close the extracellular gate. Unwound regions approximately half way
across the transmembrane helices TM1, TM5, TM6, and TM7 form twisting hinges to rearrange
around bound substrate and allow TM1a to swing open and release substrate into the cytoplasm
(Forrest et al., 2008; Kazmier et al., 2014).
Inhibitor bound structures of dDAT and hSERT are in outward-open conformations with core TM
helices preventing occlusion of the binding site and provide insight into transport-unfavourable con-
formations. In the nortriptyline bound dDAT structure (Penmatsa et al., 2013), there is a 10 Å open-
ing compared to the occluded substrate bound structure of LeuT (Yamashita et al., 2005), which
suggests that typical inhibitors of this family bind in the central cavity to stop transport by prevent-
ing the closure of the extracellular gate. Bioactive lipid inhibitors are structurally dissimilar from typi-
cal inhibitors and the question arises as to how they inhibit GlyT2. We recently showed, using
molecular dynamics (MD), that the bioactive lipids NAGly and oleoyl-L-Carnitine (OLCarn) embedded
in membranes containing GlyT2 do not perturb the biophysical properties of the bilayer, or alter the
structure of GlyT2, despite being present at a concentration an order of magnitude higher than the
IC50 for OLCarn inhibition of GlyT2 (Schumann-Gillett and O’Mara, 2019). We have also demon-
strated that, while the compounds have a high apparent affinity for GlyT2, the closely related glycine
transporter GlyT1 is insensitive to the acyl amino acids (Mostyn et al., 2017; Mostyn et al., 2019).
This suggests that the compounds do not cause a general disruption of the membrane, but rather
their inhibitory effects are mediated by binding to a specific site on GlyT2.
The mechanism of inhibition has been investigated for NAGly and oleoyl-L-lysine (OLLys) and in
both cases the lipids are not competitive (Mostyn et al., 2019; Wiles et al., 2006), suggesting the
compounds bind to a separate site to that of the substrate glycine, however this site remains elusive.
We have demonstrated that chimeric GlyT2 transporters containing EL4 from GlyT1 are insensitive
to inhibition by NAGly and OLCarn (Carland et al., 2013; Edington et al., 2009). Furthermore, a
single conservative point mutation in EL4 of GlyT2, I545L, results in transporters with reduced sensi-
tivity to lipid inhibitors. Bioactive lipids may therefore inhibit GlyT2 by binding at a site that influen-
ces the substantial conformational changes of EL4 required for transport.
In this study, we used a mutagenesis approach in combination with ligand docking and MD simu-
lations of a GlyT2 homology model to understand how acyl amino acid inhibitors interact with GlyT2.
Our results resolve differences in structure activity for inhibitors with varying amino acid head
groups, and we show that bioactive lipids bind to a novel extracellular allosteric site on the
transporter.
Results
Screening GlyT2 point mutations
The binding site for the allosteric serotonin reuptake inhibitor, (S)-citalopram, lies in the extracellular
facing vestibule of SERT, formed by residues from TM1b, TM6a, TM10, and TM11 (Coleman et al.,
2016). To determine if bioactive lipids inhibit GlyT2 by binding to this ‘vestibule allosteric site,’ cor-
responding residues in GlyT2 were mutated to remove potential interactions. OLCarn contains a
bulky, zwitterionic head group conjugated to an oleoyl lipid tail, and was used as a screen to test
mutant transporters for sensitivity to inhibition. None of the transporters containing mutations in the
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Figure 1. Defining the bioactive lipid binding site. (a) Inhibition of GlyT2 by 1 mM oleoyl L-carnitine. Transporters were WT or with mutations to the
vestibule allosteric site (VAS) or adjacent to EL4. The reduced glycine transport currents were normalised to the current elicited by glycine alone. Data
represented are means ± SEM with ****p<0.001 following a one way ANOVA test. (b–e) All lipid inhibitors docked to GlyT2 and burrowed into an area
between EL4, TM1, TM5, TM7, and TM8 during 100 ns of simulation. (b) The initial docked poses, viewed top down from the extracellular side of GlyT2
Figure 1 continued on next page
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vestibule allosteric site display any change in inhibition compared to WT (Figure 1a). To investigate
alternate sites on GlyT2 we used the observation that EL4 of GlyT2 has been shown to influence sen-
sitivity to OLCarn and NAGly (Carland et al., 2013; Edington et al., 2009). A selection of mutations
were made to residues in close proximity to EL4 that met one or a number of other criteria: residues
should be accessible in the outward-facing conformation; residues which are not conserved between
GlyT1 and GlyT2, and could account for differential selectivity of the inhibitors; aromatic residues,
that could explain the structure activity from Mostyn et al. (2019), where the most potent acyl
amino acids contained positively charged or aromatic head groups; and residues that are in regions
of GlyT2 that have important conformational roles in the transport cycle (residues shown in Fig-
ure 1—figure supplements 2 and 3). Mutations to GlyT2 residues were made either to resemble
GlyT1, or to remove potential interactions with bioactive lipids but not disrupt the overall transport
activity, often using substitutions present in the bacterial homologue, LeuT.
For the ‘EL4 adjacent’ mutations, none of the transporters containing mutations in TM1 or TM3
displayed any change in OLCarn sensitivity compared to WT. Inhibition of F424V(TM5), R439L(TM5),
E552A(EL4), and F562L(TM8) transporters were also comparable to WT. Conversely, mutations to a
cluster of residues on the extracellular halves of TM5 and TM8, and the neighbouring EL4b pro-
duced transporters that were less sensitive to inhibition by OLCarn, with inhibition only reaching
14.9–29.0% for F428A(TM5), V432A(TM5), Y550L(EL4), P561S(TM8), W563L(TM8), and L569F(TM8)
mutants (Figure 1a).
Figure 1 continued
(grey surface). Sections of TM1, TM5, and TM7 are cut away in (b–d) to show the docking cavity (transparent surface). (c) The initial docked poses of
OLLys (orange sticks), OLTrp (green sticks), OLLeu (blue sticks), and OLSer (magenta sticks) overlaid on GlyT2. (d) The conformations of the lipid
inhibitors after 100 ns of unrestrained MD simulation, overlaid on GlyT2 from the OLLys simulation. (e) A close-up view of the inhibitors following 100 ns
of simulation, with surrounding TM helices, including those cut away in panels (b–d), shown as a coloured surface. (f–g) Map of key regions in the
extracellular allosteric site. (f) 3D arrangement of residues within 4 Å of OLLys (black sticks) following 100 ns of simulation. Residues have side chains
shown as sticks, with side chains coloured TM1 (red), TM5 (yellow), TM7 (purple), EL4 (orange), TM8 (green). V523 is a backbone interaction. F428, R439,
and L569 are >4 Å but shown for reference. (g) 2D representation, with residues studied via mutagenesis outlined in black.
DOI: https://doi.org/10.7554/eLife.47150.002
The following figure supplements are available for figure 1:
Figure supplement 1. Protonation states of OLLys (orange), OLTrp (green) OLLeu (blue), and OLSer (magenta) used in the docking and molecular
dynamics simulations.
DOI: https://doi.org/10.7554/eLife.47150.003
Figure supplement 2. Location of mutated residues on GlyT2.
DOI: https://doi.org/10.7554/eLife.47150.004
Figure supplement 3. Sequence alignment of LeuT, hSERT, dDAT, hDAT, GlyT2, and GlyT1.
DOI: https://doi.org/10.7554/eLife.47150.005
Figure supplement 4. The search space for the docking to the GlyT2 homology model (grey ribbons) was defined as a rectangular box (green/red/
blue shaded walls) near mutated residues on EL4, TM5, TM7 and TM8.
DOI: https://doi.org/10.7554/eLife.47150.006
Figure supplement 5. Resulting poses from docking to the GlyT2 homology model (grey ribbons), with EL4 highlighted in orange.
DOI: https://doi.org/10.7554/eLife.47150.007
Figure supplement 6. After 100 ns of simulation, GlyT2 retained a similar overall conformation when the lipid inhibitors were present (GlyT2 with OLLys
- blue) or absent (GlyT2 WT - wheat), as shown.
DOI: https://doi.org/10.7554/eLife.47150.008
Figure supplement 7. The root-mean-square deviation (RMSD) of GlyT2 with no lipid inhibitor bound or when the lipid inhibitor is bound with tail
inserted into extracellular pocket and directed towards TM5.
DOI: https://doi.org/10.7554/eLife.47150.009
Figure supplement 8. The root-mean-square deviation (RMSD) of GlyT2 when the lipid inhibitor is bound with the head inserted into extracellular
pocket.
DOI: https://doi.org/10.7554/eLife.47150.010
Figure supplement 9. The root-mean-square deviation (RMSD) of GlyT2 when the lipid inhibitor is bound with tail inserted into extracellular pocket
and directed towards EL4.
DOI: https://doi.org/10.7554/eLife.47150.011
Figure supplement 10. The root-mean-square fluctuation (RMSF) of GlyT2 diverged in specific, local regions of GlyT2 when no lipid inhibitor is bound.
DOI: https://doi.org/10.7554/eLife.47150.012
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For each mutant transporter with reduced sensitivity at the screening dose, concentration
response curves for select acyl amino acid inhibitors were measured, with IC50 and maximal inhibi-
tion values presented in Supplementary file 2. The EC50 values of glycine for these mutant trans-
porters are not significantly different to WT suggesting their mechanism of transport is not impaired
(Supplementary file 3). Mutation of P429(TM5) to alanine, and F567(TM8) to alanine, valine, or leu-
cine generated transporters that did not produce glycine dependent transport currents and were
unable to be examined.
Computational analysis of the proposed GlyT2 binding site
To further characterise the molecular basis of bioactive lipid-protein interactions, representative acyl
amino acids with varying head groups were docked into our published GlyT2 homology model
(Carland et al., 2018; Subramanian et al., 2016) generated from the nortriptyline bound dDAT
structure (Penmatsa et al., 2013). The location for docking was selected based on the mutagenesis
results. Specifically, OLLys, oleoyl L-Leucine (OLLeu), oleoyl L-Tryptophan (OLTrp), and oleoyl L-Serine
(OLSer) (Figure 1b–c) were each docked into an area that encompassed the extracellular and upper-
leaflet embedded regions of TM5, TM8, and EL4 of GlyT2 (Figure 1—figure supplement 4), as this
region includes the cluster of differentially sensitive residues identified using mutagenesis, that is
F428 (TM5), V432 (TM5), I545 (EL4), Y550 (EL4), P561 (TM8),W563 (TM8), and L569 (TM8). The stabil-
ities of the binding locations were assessed using unrestrained MD simulations (performed in tripli-
cate) of the inhibitor/protein complexes, embedded in a bilayer containing POPC and 20 mol %
cholesterol. As the head of the inhibitor docked in a similar location for each class of inhibitor, the
positions of the inhibitors can be classified into three general poses based on the orientation of the
tail: 1) head inserted into extracellular pocket, with the tail exposed to water; 2) tail inserted into
extracellular pocket and the double-bond in close proximity to I545 of EL4; and 3) tail inserted into
extracellular pocket, with the double-bond in close proximity to TM5 and the protein-lipid interface
(Figure 1—figure supplement 5). Regardless of the docked position, the backbone RMSD of GlyT2
remained below 3.8 Å, indicating that GlyT2 did not display any large-scale conformational changes
when OLLys, OLTrp, OLLeu, or OLSer are bound, compared to when each inhibitor was absent (see
Figure 1—figure supplements 6–10).
Furthermore, regardless of the initial position of the inhibitor, the initial docked interaction is not
maintained. In all simulations of OLLys, OLTrp, OLLeu, or OLSer which were initiated from docked
poses, the inhibitor moved out of the pocket, or reoriented so that the lipid tail was directed
towards TM5. Overall, MD simulations of the docked poses with the lipid inhibitor oriented head-
first in the extracellular pocket, with the tail exposed to water, or with the tail orientated so the dou-
ble bond was in close proximity to I545 of EL4, indicates that neither orientation reflects stable inhib-
itor binding.
When the inhibitors docked with the tail directed towards TM5, the lipid inhibitors move from
their initial docked pose and burrow into a novel extracellular allosteric site, with their tail wedged in
a hydrophobic cavity between TM5, TM7, and TM8 (Figure 1d–e) and remained in that conforma-
tion for the remainder of the simulation. This was observed in all replicate simulations of OLLeu,
OLLys and OLTrp, and in 2 of the three replica simulations of OLSer. It should be noted that the ini-
tial docked position of OLSer in the extracellular pocket is notably shallower than the other lipid
inhibitors (Figure 1c). In each case when the lipid inhibitor binds in the extracellular allosteric site,
the amino acid head groups of the bioactive lipids remain close to the bilayer/water interface and
interact with the extracellular edges of TM5, TM7, TM8, and EL4. As the lipid inhibitors preferentially
bind in this pocket, further discussion herein will focus on these simulations.
Analysis of the MD simulations shows that the binding of each lipid inhibitor to GlyT2 is mediated
by several key amino acids (see Supplementary file 4). The lipids adopt a kinked structure with the
head group interacting with a number of aromatic amino acids, as well as the side chain of R531 and
backbone of V523, while the acyl tail is stabilised by aliphatic residues lining the TM5/7/8 pocket
(Figure 1f–g).
I545 on EL4 facilitates binding into the extracellular allosteric site
Access of lipids to the TM5/7/8 cavity is influenced by I545 in EL4 where I545 appears to sterically
restrict the volume of the acyl chain binding pocket for OLLys, OLTrp, and OLSer. In all MD
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simulations, the side chain of I545 remains pointed inward (e.g. Figure 2a–b) to interact with the
acyl chain of each acyl amino acid. In this way, I545 appears to stabilise the acyl amino acid in the
hydrophobic TM5/7/8 cavity, preventing the lipid from inserting into the centre of GlyT2. The beta-
branched structure of I545 also facilitates the tail insertion into the TM5/7/8 cavity, with substantial
curvature of the acyl chain occurring proximal to I545 (Figures 1f and 2b). For OLSer, the initial
Figure 2. I545 facilitates lipid inhibitor binding to the extracellular allosteric site. (a) Docked position of OLLys (magenta spheres) where the acyl tail is
folded at the double bond, and neighbours EL4. (b). Throughout the simulation I545 (cyan spheres) faces towards the binding cavity and interacts with
the acyl tail, where there is a substantial kink adjacent to the head group. (c) Overlay showing snapshots of OLSer as it moves from the docked position
(0 ns, green sticks) and into the cavity between TM5/7/8 of WT GlyT2 (50 ns, red sticks; 100 ns, blue sticks). I545 is shown as cyan spheres. TM5 and TM7
are transparent to show the cavity. (d-f) The I545L mutation (cyan spheres) sterically blocks deep insertion into the cavity. (d) Docked position of OLLys
(magenta spheres) on the I545L mutant transporter and (e) following 100 ns of simulation – OLLys maintains head group interactions but the acyl tail
adopts a hairpin structure to bind at a shallower cavity. (f) Overlay of OLSer as it leaves the docked position and cannot insert into the I545L mutant
GlyT2, but instead idles above in the extracellular compartment. Coloured as in (c). (g-h) Acyl amino acids inhibit glycine transport currents of WT and
mutant GlyT1 and GlyT2 transporters. Glycine transport currents were measured in the presence of lipids to generate concentration inhibition curves for
(e). OLCarn (˜) and (f) oleoyl L-Lys (□). GlyT2 WT is shown in black, GlyT1 WT is in grey, I545L (G2) is in teal, and L425I (G1) in pink.
DOI: https://doi.org/10.7554/eLife.47150.013
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docked pose of the lipid is located at the open-
ing to the extracellular allosteric site. OLSer bur-
rows deeper into the binding site throughout the
100 ns simulation, facilitated by I545, which sug-
gests insertion is an important step mediated by
interactions with the acyl tail (Figure 2c,
Video 1).
I545 is critical for inhibition by NAGly and
OLCarn, with a conservative leucine mutation
abolishing lipid inhibition (Carland et al., 2013;
Edington et al., 2009). If this residue is essential
to facilitate acyl amino acid burrowing into an
inhibitory conformation, then its presence should
be required for all bioactive lipids. To confirm
this, a selection of synthetic acyl amino acids
were applied to oocytes expressing the I545L mutant (Figure 2g–h, Supplementary file 1). A
diverse range of bioactive lipid inhibitors (OLVal, OLAsp, or OLTrp) have reduced apparent affinities
and maximal level of inhibition. For OLLys the potency is ~17 fold lower, yet 80.7% inhibition could
still be attained, which suggests an inhibitory conformation can still be achieved with a leucine in this
position, but the binding interaction is reduced.
GlyT2 lipid inhibitors do not inhibit GlyT1 even though the majority of residues in the extracellular
allosteric site are common between GlyT1 and GlyT2, suggesting subtle substitutions (such as I545
for leucine) may impart the differential selectivity (Figure 1—figure supplement 3). To further inves-
tigate the role of I545, OLLys, OLLeu, OLTrp and OLSer were docked to the I545L GlyT2 mutant and
simulated using the same protocol as for WT GlyT2. While the lipids initially docked in similar poses
to that seen for WT GlyT2, they adopt different positions upon MD simulation. In particular, the ini-
tial docked pose of OLSer positions the lipid at the opening to the extracellular allosteric site, how-
ever steric hindrance from I545L blocks OLSer from burrowing deeper into the binding site in 2 of
the three replica simulations for the I545L mutation, and instead, OLSer moves away from the extra-
cellular allosteric site (Figure 2f, Video 2). In the single simulation where OLSer did not dissociate
from the allosteric pocket of the I545L mutant, the acyl tail only partially entered the hydrophobic
TM5/7/8 cavity, while the head group did not interact with the surrounding amino acids, but was
partially inserted into the surrounding membrane. Conversely, OLLys is able to bind in the extracellu-
lar allosteric site of the I545L mutant GlyT2, and maintains head group interactions with residues in
EL4 and TM8 (Figure 2d–e). However, the presence of the I545L mutation prevents full insertion of
the OLLys tail into the lipid binding pocket, which instead adopts a hairpin conformation (compare
Figure 2b–2e). This is consistent with the ability of OLLys to retain inhibition of the I545L mutant,
albeit with reduced potency, and may explain how more potent inhibition can be achieved with a
deeper penetrating acyl amino acid.
To further investigate selectivity between GlyT2 and GlyT1, we created the corresponding reverse
GlyT1 mutation, L425I. For NOGly or OLTrp, L425I is insensitive, similar to the WT GlyT1 response;
but inhibition of GlyT1 L425I by OLCarn is com-
parable to WT GlyT2 (IC50195 nM; max. inhibition
74.6%). While OLLys reaches a maximal level of
inhibition similar to WT GlyT2 (95.6%), the appar-
ent affinity is 9-fold lower. Though clearly impor-
tant, the I545 to leucine is not the only molecular
determinant for bioactive lipid binding at GlyT2.
The head group of bioactive lipid
inhibitors is coordinated by
aromatic residues in EL4 and TM8
Throughout the MD simulations, the amino acid
head group of the bioactive lipids consistently
interacts with Y550 for >94% of the total simula-
tion time. Y550 lies approximately one turn of the
Video 1. OLSer binding to WT GlyT2.
DOI: https://doi.org/10.7554/eLife.47150.014
Video 2. OLSer binding to I545L GlyT2.
DOI: https://doi.org/10.7554/eLife.47150.015
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helix up from I545 and faces away from the extracellular vestibule and into the extracellular allosteric
site in the GlyT2 homology model (Subramanian et al., 2016). Substitution of Y550 with a leucine
reduces both the apparent affinity and maximal level of inhibition for all 10 bioactive lipid inhibitors
tested (Figure 3d–e, Supplementary file 1). This mutation affects acyl-amino acids with a range of
different side chains suggesting an interaction is formed between the aromatic ring of Y550, and a
shared moiety of the inhibitor, likely to be the amino acid backbone of the lipid head group.
The distance between the C3 of the aromatic ring of Y550 and the Ca amino acid backbone of
the acyl-amino acid throughout the MD simulations is shown in Figure 3b. The distance ranges from
5 to 7 Å, for OLLys and OLLeu, indicating a tighter coordination for these acyl amino acids. For
OLTrp the distance is ~10 Å, while Y550 does not interact with OLSer (>15 Å; Figure 3c).
Figure 3. Y550 coordinates the amino acid head group. (a) Snapshot showing how the distance between C3 on the acyl-amino acids (OLLys shown
here, in orange sticks) and Ca on Y550 was calculated. (b) The OLLys/OLLeu C3 (orange and blue lines, respectively) were closer to the Y550 ring than
OLTrp/OLSer C3 (green and magenta lines, respectively) during the simulations, with the average distance shown in (c). (d-e) Acyl amino acid inhibition
of glycine transport currents of Y550L mutant transporters. Glycine transport currents were measured in the presence of lipids to generate
concentration inhibition curves for (d) OLLys (□), ODLys ( ), OLTrp (à), (e). OLSer (), and OLAsp (r). GlyT2 WT is shown in black, Y550L is in blue.
DOI: https://doi.org/10.7554/eLife.47150.016
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As EL4 shifts into the vestibule as part of the transport cycle, it packs tightly against the core heli-
ces, including TM8, to close the extracellular gate (Forrest et al., 2008; Krishnamurthy and
Gouaux, 2012). I545 and Y550 in EL4 are oriented towards the top half of TM8, near P561 and
W563, and mutations of these TM8 residues differentially affect acyl amino acid inhibition. The
W563L mutation has no effect on inhibition by lipids containing nucleophilic or acidic amino acid
head groups, OLSer and OLAsp, while the activity of OLCarn, OLTrp, and ODLys inhibitors are all
reduced compared to WT GlyT2 (Figure 4g–h, Supplementary file 1). The differential effects of the
W563L mutation may be due to the contribution of p electrons for p-p and cation-p interactions with
aromatic or positively charged amino acid side chains of the most potent lipid inhibitors.
Figure 4. W563 and R439 act as ‘gates’ to stabilise the acyl amino acids in their binding cavity. (a-d) Snapshots of interactions between bioactive lipids
(spheres) and W563 and R439 (cyan sticks) during the simulation. GlyT2 helices are coloured EL4 (orange), TM5 (yellow), TM7 (purple), and TM8
(green). (e) The distance between the centre of mass of W563 and R439 over 100 ns when inhibitors were bound. The control (no inhibitor) is included in
black. (f) Average distances throughout the simulations. (g–h). Acyl amino acid inhibition of glycine transport currents of W563L mutant transporters.
Glycine transport currents were measured in the presence of lipids to generate concentration inhibition curves for (g) OLLys (□), ODLys ( ), OLTrp
(à), (h). OLSer (), and OLAsp (r). GlyT2 WT is shown in black, W563L is in red.
DOI: https://doi.org/10.7554/eLife.47150.017
Mostyn et al. eLife 2019;8:e47150. DOI: https://doi.org/10.7554/eLife.47150 9 of 22
Research article Biochemistry and Chemical Biology
Figure 5. Residues in TM5 and TM8 mediate inter-helical contacts and shape the acyl tail binding cavity. (a-c) Acyl amino acids inhibit glycine transport
currents of F428A mutant GlyT2 transporters. Glycine transport currents were measured in the presence of lipids to generate concentration inhibition
curves for (a). OLCarn (˜),oleoyl L-Lys (□), (b) NOGly ( ), C18 w8 Gly (à), C18 w10 Gly (⊠), (c) C16 w7 Gly (r), C16 w11 Gly () and C14 w5 Gly (+).
GlyT2 WT is shown in black and F428A is in orange. (d) Overlay of GlyT2 in the absence of inhibitor (wheat helices) with OLLys (magenta spheres)
Figure 5 continued on next page
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Molecular dynamics simulations show that W563 is particularly important for stabilising head
group interactions in the binding site. In control simulations without the acyl amino acid inhibitors,
the side chain of W563 associates with the R439 side chain through a cation-p interaction, forming a
physical barrier, or ‘gate’, which limits the volume and accessibility of the cavity between TM5 and
TM8. When lipid inhibitors are present, the distance between W563 and R439 remains between
7.0 ± 0.3 Å and 9.7 ± 1.2 Å (Figure 4f), however the precise nature of the interaction between W563
and R439 is dependent upon the amino acid head group of the bioactive lipid. OLLys binding
changes the interaction between TM5 and TM8, where the indole group of W563 instead prefers to
interact with the OLLys side chain for 71% of the total simulation time (Figure 4a). For OLSer, the
polar hydroxymethyl group in the side chain also inserts between the R439 and W563 side chains as
shown in Figure 4d and interacts with these residues for >50% of the total simulation time. The
hydrophobic OLLeu side chain is within 4 Å of W563 and R439 for >90% of the total simulation time.
However OLLeu does not directly interact with these residues and instead faces towards the centre
of GlyT2 (Figure 4c). In the case of OLTrp however, the aromatic side chain forms a cation-p planar
stacking arrangement, where the guanadinium group of R439 is sandwiched between OLTrp and
the aromatic ring of W563 (Figure 4b). Notably, the interaction between R439 and OLTrp persists
for the total simulation time. While the potency of OLTrp is greatly affected by the W563L mutation,
inhibition of the R439L mutant is unchanged compared to WT (Supplementary file 1). This suggests
that W563 is more important for governing head group interactions, or that there are compensatory
interactions when the postive charge of R439 is lost.
For the P561S mutant transporter, inhibition by NOGly and OLVal is comparable to WT GlyT2,
whereas lipids with larger or more sterically restricted head groups (OLCarn, OLTrp, and ODLys)
have reduced apparent affinities (Supplementary file 1). P561 is the first residue at the top of TM8,
where the helix breaks into a small unwound region before EL4 begins. Mutation of P561 may there-
fore alter the connection between TM8 and EL4, extending the helix and changing the shape of the
gap between the two domains. This could limit the pocket size available to acyl amino acid inhibitors
with larger head groups.
Acyl tail binding cavity
F428 (TM5), V432 (TM5), and L569 (TM8) are located approximately in the middle of their respective
transmembrane helices in a highly hydrophobic region of GlyT2. While V432A displays reduced sen-
sitivity to bioactive lipid inhibitors with a range of acyl tails, both the L569F and F428A mutations
show reduced inhibition by acyl amino acids containing the oleoyl (C18 w9) tail, but have no effect
on NAGly, which contains a polyunsaturated C20 arachidonyl tail (Supplementary file 1). This effect
is most pronounced for F428A, and so this mutant was further explored using a range of glycine con-
jugated lipids with acyl chains that varied in their length and position of the monounsaturated dou-
ble bond (Mostyn et al., 2017).
All C18 acyl-glycine inhibitors have reduced apparent affinities for the F428A transporter. A com-
parison between acyl-glycine analogues with double bonds in the w8, 9, and 10 positions shows a
striking relationship demonstrating that a double bond in w8 position is markedly affected whilst a
double bond in the w10 position is only mildly affected by the mutation (Figure 5b). For C16 acyl-
glycine inhibitors, the activity is also altered by the position of the double bond; the w11 compound
has activity on F428A comparable to WT GlyT2, but potency and maximal inhibition of the lipid with
a double bond in the w7 position is considerably reduced (IC505.8 mM, maximal inhibition 56.5%).
The sensitivity of F428A to the C14 acyl-glycine is also reduced (IC50 >30 mM) (Figure 5c). The com-
pounds that have the most marked reduction in activity at F428A transporters all possess a double
bond the approximate same distance from the head group, which would create a kink that needs to
be accommodated by a particular cavity shape.
Figure 5 continued
bound at 100 ns (blue helices). TM8 regions were aligned to show the relative movement of TM5. (e) Distances between the extracellular edges of TM5
(T442) and TM8 (S560) calculated from their Ca. (f) Distances between the middle of TM5 (F428) and TM8 (L569) calculated from their Ca. (g) Distances
between the last carbon of the lipid inhibitor tail and the bottom of the extracellular allosteric pocket (Ca of V432).
DOI: https://doi.org/10.7554/eLife.47150.018
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The previously mentioned MD simulations initiated from docking of four acyl-amino acid inhibitors
reveal that V432 lies at the base of the lipid binding pocket facing towards the acyl tail, while F428
and L569 flank the pocket and are exposed to the centre of the hydrophobic core of the lipid
bilayer. Importantly, F428 (TM5) and L569 (TM8) contact each other to mediate the TM5/TM8 helix-
helix interaction. Upon insertion of the lipid inhibitors into the extracellular allosteric site, the extra-
cellular regions of TM5 and TM8 shift apart, moving ~4 Å after 100 ns simulation (Figure 5d–e).
F428 and L569 however, remain tightly associated to maintain contacts at the mid-point between
these helices, and create a snug binding cavity for the acyl tail (Figure 5f). Indeed, the terminal car-
bon of the lipid inhibitor tail remains within 15 Å of V432 throughout the simulation (Figure 5g).
Mutation of these inter-helical contact residues may therefore select for certain tails through changes
in the volume, shape and acyl chain accessibility of the binding pocket.
Discussion
Acyl amino acids are a new class of glycine transport inhibitors that have analgesic effects in rodent
models of neuropathic and inflammatory pain with minimal overt side effects (Mostyn et al., 2019;
Figure 6. Bioactive lipid inhibitors bind to GlyT2 at an extracellular allosteric site, separate from the ‘classical’
central substrate and vestibule allosteric binding sites. OLLys (orange spheres) is bound to GlyT2 (100 ns). The
binding location of s-citalopram at the substrate (maroon spheres) and vestibule allosteric (blue spheres) sites is
superimposed from the serotonin transporter structure (PDB: 5173). GlyT2 is shown as transparent cartoon, with
selected regions coloured: TM1 (red), TM5 (yellow), TM7 (purple), TM8 (green), and EL4 (orange).
DOI: https://doi.org/10.7554/eLife.47150.019
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Succar et al., 2007; Vuong et al., 2008). In this study, we have explored how these compounds
bind to, and inhibit, the glycine transporter, GlyT2. The acyl amino acids consist of two distinct ele-
ments: an unsaturated acyl tail and the amino acid head group. Both elements are essential for inhi-
bition, with the length of the tail, the position of the double bond, and the chemical nature of the
amino acid all influencing potency and efficacy (Mostyn et al., 2017; Mostyn et al., 2019). By study-
ing the effects of a series of mutant transporters in TM5, TM8, and EL4, in combination with docking
studies and MD, we have been able to identify structural elements in the transporter that determine
head group and acyl tail specificity.
Mutations of I545 and Y550 reduce the inhibitory action of all inhibitors, suggesting that these
residues interact with common features of the bioactive lipids. MD simulations suggest that I545
plays a role in steering the acyl tail into the TM5/7/8 pocket, and that a conservative mutation of this
residue can cause a striking restriction of binding. Additionally, Y550 can coordinate the amino acid
backbone of the bioactive lipid head group. In MD simulations, the head groups of the lipid inhibi-
tors are stabilised by an aromatic cage formed by residues W563 (TM8), F526 (TM7), and Y550 (EL4)
as well as the positively charged R439 (TM5), and R531 (EL4) which has previously been shown to be
important for inhibition (Carland et al., 2013; Edington et al., 2009). Mutation of W563 has the
greatest effects on inhibitors with positively charged or aromatic amino acid head groups whilst pro-
ducing no effect on the efficacy of lipids containing aliphatic or uncharged polar head groups; this
suggests the indole ring of W563 provides additional contacts for the side chains of the most potent
inhibitors.
The stability of the extracellular allosteric site relies on inter-helical connections between EL4-
TM8 and TM5-TM8. The size and configuration of the amino acid head group accommodated in this
pocket could be altered with mutation to P561, an important helix breaking residue at the top of
TM8. Similarly, F428 (TM5) and L569 (TM8) lie just outside the base of the cavity and form inter-heli-
cal contacts. We predict that mutation of these inter-helical contact residues may change the shape
and volume of the acyl binding pocket, resulting in mutant transporters with altered head-specific
and tail-specific sensitivity.
In each of the MD simulations, the bioactive lipids were docked into the region identified in the
mutagenesis studies, and then allowed to find their optimal binding location following 100 ns of sim-
ulation. OLLys, OLTrp, and OLLeu were docked into the extracellular allosteric site and remained
bound in the cavity for the full 100 ns of simulation. However, for OLSer, the lipid initially binds with
the acyl tail partially buried within the cavity with the head group poking out to explore both the
membrane and extracellular space. After 100 ns of simulation, OLSer migrates into GlyT2 (Video 1)
to form a more stable interaction where the serine head group interacts with TM5, TM8, and EL4, as
seen with other acyl amino acids. In each case, the acyl tails of bioactive lipids penetrate the trans-
porter to forge a deeper cavity, driving apart TM5 and TM8 (Figure 5d–e). For the I545L trans-
porter, bioactive lipids either did not bind in the extracellular allosteric site, or remained loosely
associated in a shallow pocket with the acyl tails in a hairpin (Figure 2e–f, Video 2). Therefore, we
propose that the formation of this deep binding pocket is unique to GlyT2, and may explain the
selectivity of inhibition over GlyT1.
The identification of the acyl amino acid binding site by mutagenesis and MD of lipid docking
raises questions about the mechanism of inhibition, and whether such a cavity exists in other closely
related neurotransmitter transporters. In the transition from the outward-occluded state to the
inward-open state in the bacterial homologue of the SLC6 family (LeuT), TM5 and TM7 undergo sub-
stantial conformational changes causing these helices to bend, and EL4 to pack into the central vesti-
bule to close off the extracellular pathway (Forrest et al., 2008; Krishnamurthy and Gouaux,
2012). Furthermore, in both LeuT and the multi-hydrophobic amino acid transporter, MhsT, the
intracellular half of TM5 unwinds via a conserved Gly-X9-Pro motif during the transition to the inward
open state to allow release of Na+ ions and substrate (Malinauskaite et al., 2014; Zeppelin et al.,
2018; Stolzenberg et al., 2017). Binding of a bioactive lipid to the extracellular allosteric binding
site formed by TM5, TM7, TM8, and EL4 may therefore restrict the movements of EL4 and/or the
unwinding of TM5 to inhibit the transport mechanism. Perturbation of this region via lipid binding
may alter the dynamics of GlyT2, and could be a potential mechanism of inhibition that would slow,
but not completely block, transport as in the case of a partial inhibitor.
Cholesterol has also been demonstrated to modulate DAT and SERT. A crystal structure of dDAT
revealed a cholesterol molecule coordinated in an inner-leaflet, membrane exposed, cleft between
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TM1a, TM5, and TM7 (Penmatsa et al., 2013). Superimposition of the dDAT structure with the
inward-open structure of LeuT (Krishnamurthy and Gouaux, 2012) reveals a potential regulatory
mechanism for cholesterol, where cholesterol may be an endogenous modulator of the dopamine
transporter by inhibiting the transition to an inward-facing conformation, which has since been sup-
ported using molecular dynamics (Zeppelin et al., 2018). The allosteric site for cholesterol is an
inner leaflet, membrane exposed site on the surface of dDAT, whereas the bioactive lipid site identi-
fied in this study is buried between helices. The lipid binding site on GlyT2 is also distinct from the
central substrate binding or vestibule allosteric sites (Figure 6, Figure 1—figure supplement 3),
and represents a novel extracellular allosteric site for the SLC6 family of transporters.
With the exception of I545, the majority of residues that have a significant effect on the activity of
acyl amino acids are conserved among many SLC6 transporters, which suggests major features of
the binding site are common. It is striking that the reverse L425I mutation in GlyT1 is sufficient to
impart sensitivity of some of the inhibitors, which suggests the binding site must be mostly pre-
formed in GlyT1, and that subtle conformational differences may accommodate different bioactive
lipids. This also suggests that it may be possible to exploit these subtle differences in the structure
of the extracellular allosteric site between other SLC6 members to design novel compounds that
inhibit neurotransmitter transporters in a fundamentally different manner to the classical transport
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Lipids
N-arachidonyl glycine and N-oleoyl glycine were obtained from Sapphire Biosciences (NSW, Aus-
tralia); and oleoyl L-carnitine was obtained from Larodan Fine Chemicals (Malmo, Sweden). All other
acyl amino acids were synthesised as previously described by Mostyn, Rawling, and colleagues
(Mostyn et al., 2017; Mostyn et al., 2019).
Mostyn et al. eLife 2019;8:e47150. DOI: https://doi.org/10.7554/eLife.47150 15 of 22
Research article Biochemistry and Chemical Biology
Creation of wild type (WT) or mutant mRNA encoding glycine
transporters
Human GlyT1b or GlyT2a (herein referred to as GlyT1 and GlyT2) cDNA were sub-cloned into the
plasmid oocyte transcription vector (pOTV). Site-directed mutagenesis was performed using tradi-
tional PCR techniques, and sequences confirmed by the Australian Genome Research Facility (Syd-
ney, Australia). WT and mutant plasmid DNA were linearised with SpeI (New England Biolabs
(Genesearch) Arundel, Australia) and RNA transcribed by T7 RNA polymerase using the mMessa-
gemMachine kit (Ambion, TX, USA).
Two electrode voltage clamp electrophysiology
Oocytes were extracted from female Xenopus laevis frogs and detached from follicle cell containing
lobes by digestion with 2 mg/mL collagenase A (Boehringer, Mannheim, Germany). Defoliculated
stage V-VI oocytes were injected with 4.6 ng of cRNA encoding WT or mutant transporter (Drum-
mond Nanoinject, Drummond Scientific Co., Broomall, PA, USA). Surgical proceedures have been
approved by the University of Sydney Animal Ethics Committee (protocol 2016/970). The oocytes
were stored at 16–18˚C for 2–5 days in ND96 solution (96 mM NaCl, 2 mM KCL, 1 mM MgCl2, 1.8
mM CaCl2, 5 mM HEPES, pH 7.55), supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophyl-
line, 50 mg/mL gentamicin and 100 mM/mL tetracycline.
2–5 days following injection, glycine transport currents were measured at  60 mV using Gene-
clamp 500 amplifier (Axon Instruments, Foster City, CA, USA) with a Powerlab 2/20 chart recorder
(ADInstruments, Sydney, Australia) and chart software (ADInstruments). All data were subsequently
analysed using GraphPad Prism 7.02 (GraphPad Software, San Diego, CA).
Concentration responses
The function of each mutant transporter was tested by measuring glycine concentration dependent
transport currents in ND96 (96 mM Na+) to drive transport. EC50 values were determined using the
modified Michaelis-Menten equation:
I¼ ð½GIy:ImaxÞ=EC50þ½GIy (1)
where I is current (nA), [Gly] is the concentration of glycine, Imax is the current generated by a maxi-
mal concentration of glycine (300 mM) and EC50 is the concentration of glycine that generates a half
maximal current. Values are presented as mean ± SEM obtained fromn 3 cells from at least two
batches of oocytes. To determine if mutations affected glycine transport, one way ANOVA tests
were employed, with a Dunnett’s post-hoc test used for comparison with WT GlyT2. For L425I com-
parison with WT GlyT1 a two-tailed t-test was used. Statistical significance were represented as
p<0.05 *, p<0.01 **, p<0.001 *** etc. in the following figures.
The majority of N-acyl amino acids are not immediately reversible, and thus inhibitor concentra-
tion responses were performed using cumulative application. Glycine was first applied to establish
maximal transport current. Glycine was then co-applied with increasing concentrations of acyl amino
acid in a stepwise fashion, producing individual plateau values in response to each concentration of
inhibitor.
Inhibitor concentration responses were then fit by the method of least squares using:
Y¼BottomþðTop BottomÞ=ð1þ 10ðx LogIC50ÞÞ (2)
where X is log[acyl amino acid] (mM), Y is current normalised to glycine in the absence of inhibitor
and Top and Bottom are the maximal and minimal plateau responses respectively. This equation was
constrained to have the bottom value >0, but not = 0, as to capture partial levels of inhibition, and
the standard hill slope  1.0. Concentration response curves were thus able to generate IC50 values
as well as % maximum (max.) inhibition values.
IC50 values are presented as mean and 95% confidence intervals, and % max inhibition are pre-
sented as mean ± SEM. Data are from n  3 cells from at least two batches of oocytes. Where signif-
icant inhibition was not reached, the IC50 value is recorded as greater than the highest concentration
of acyl amino acid used. As many mutants were no longer sensitive to inhibition, significance was cal-
culated using % maximal inhibition values for each acyl amino acid. Where inhibitors were used at
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least two mutants, a one way ANOVA test with Dunnett’s post-hoc tests were used for comparison
with WT GlyT2. Where inhibitors were only tested on a single mutant, a two-tailed T-test was used
for comparison. p values are presented as p<0.05 *, p<0.01 **, p<0.001 *** etc. in
Supplementary file 1.
Molecular dynamics simulations
Molecular coordinates and topologies
The coordinates of the experimentally validated homology model of GlyT2 (in the outward-occluded
conformation) were taken from Subramanian et al. (2016) Substrate and bound ions were excluded
to determine whether acyl-amino acid interactions were competitive or non-competitive with the gly-
cine substrate. The Automated Topology Builder and Repository (ATB) (Koziara et al., 2014;
Malde et al., 2011) was used to develop united atom coordinates and parameters for oleoyl-L-
Lysine, oleoyl-L-Tryptophan, oleoyl-L-Leucine and oleoyl-L-Serine. The coordinates and topologies
are available for download from the ATB (oleoyl-L-lysine MoleculeID: 252919, oleoyl-L-tryptophan
MoleculeID: 252930, oleoyl-L-leucine MoleculeID: 252921, oleoyl-L-serine MoleculeID: 252932). To
ensure that there was no isomerisation around the cis double bond, the force constant related to
this dihedral angle in the acyl-amino acids was adjusted from 5.86 kJ/mol/rad2 to 41.80 kJ/mol/rad2.
Each lipid was simulated alone in a box of water for one ns prior to docking or further simulation to
ensure that this bond conformation was maintained. The parameters for POPC were those devel-
oped by Poger and Mark (2010), and the cholesterol parameters were obtained from the ATB
(Canzar et al., 2013; Koziara et al., 2014; Malde et al., 2011). The protonation state for all lipids
was that in which it would most likely be found at physiological pH (pH 7): POPC and oleoyl-L-Lys
were zwitterions; and oleoyl-L-Trp, oleoyl-L-Leu and oleoyl-L-Ser were deprotonated as shown in Fig-
ure 1—figure supplement 1.
Acyl-amino acid docking and molecular dynamics system setup
Each acyl-amino acid was docked to our GlyT2 model (Subramanian et al., 2016) using Autodock
vina (Trott and Olson, 2010). The acyl-amino acids were modelled in a united-atom configuration
for consistency with the GROMOS 54a7 forcefield and subsequent MD simulation, and treated as
flexible (i.e., all bonds were rotatable with the exception of the cis double bond and amide). The
docking search space on GlyT2 was defined as a box that surrounded critically important residues in
TM5, 7, 8 and EL4 such as R439 (TM5), W563 (TM8), F526 (TM7) and Y550 (EL4) (Figure 1—figure
supplement 4, that all lie within the span of the extracellular leaflet of the membrane. The number
of points that were included in the x- y- and z-directions of the docking box were: 14, 14 and 24
respectively. The N-terminus of GlyT2 was capped with a neutral acetyl group and the C-terminus
was capped with a neutral amine group. Following docking, the resulting poses were categorised
based on their general orientations (Figure 1—figure supplement 5) and one pose from each cate-
gory was selected via manual inspection and simulated for each inhibitor.
The simulations were performed using GROMACS version 2016.1 with the GROMOS 54A7 force
field for lipids and proteins (Abraham et al., 2015; Schmid et al., 2011). Each acyl-amino acid-
bound GlyT2 was embedded in a bilayer that contained 20 mol % cholesterol and 80 mol % POPC.
A control system, which lacked a bound acyl-amino acid, was also simulated. In each system, the
bilayer was oriented in the x-y plane. Each bilayer system was contained in a solvated rectangular
box. The simple point charge model was used to describe the water molecules and 0.15 M of Na+
and Cl- ions were added. The overall charge of each system was neutral. Periodic boundary condi-
tions were applied and each system was energy minimised by employing a steepest descent algo-
rithm. The systems were then equilibrated by performing a series of five one ns simulations, where
the backbone atoms of GlyT2 were restrained using sequentially descending force constants of 1000
kJ mol 1 nm 1, 500 kJ mol 1 nm 1, 100 kJ mol 1 nm 1, 50 kJ mol 1 nm 1 and 10 kJ mol 1 nm 1.
The coordinates from the final frame of each 10 kJ mol 1 nm 1 restrained simulation were used as
the starting conformation for unrestrained simulations. New velocities were assigned and unre-
strained MD simulations lasting 100 ns performed in triplicate for each system.
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Simulation details
The simulation conditions were the same as used by Schumann-Gillett and O’Mara (2019). Briefly,
the NPT ensemble was employed and the solute (acyl-amino acid-bound GlyT2 in a bilayer) and sol-
vent were separately coupled to an external temperature bath at 300 K. The Bussi-Donadio-Parri-
nello velocity rescale thermostat (Bussi et al., 2007) was used and the coupling constant was tT =
0.1 ps. The system was weakly coupled to an external pressure bath using the Berendsen thermo-
stat, which was set to 1 bar. Semi-isotropic pressure coupling was employed, isotropic in the plane
of the bilayer (x-y). The coupling constant was tT = 0.5 ps, with an isothermal compressibility of
4.5  10 5 bar. The LINCS algorithm (Hess et al., 1997) was used to constrain the covalent bond
lengths of the solute and the SETTLE algorithm was used to constrain the geometry of the water
molecules (Miyamoto and Kollman, 1992). The electrostatic and non-bonded interactions were
updated every time step. Particle mesh Ewald summation was used to calculate the electrostatic
interactions. The Lennard-Jones interactions were calculated using a 1.0 nm cut-off. Images of the
docked and simulation systems were produced using the Visual Molecular Dynamics software
(Humphrey et al., 1996), or PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC).
Analysis
All data were calculated using 1000 frames, corresponding to 100 ns of simulation. Averages were
calculated over all frames and replicates.
Root-mean-square fluctuation
To calculate the root-mean-square fluctuation (RMSF; i.e. standard deviation) of the backbone Ca
atoms of GlyT2, for each system the protein was fit to the first frame of the unrestrained 100 ns tra-
jectory, and the deviation of the Ca’s was calculated using the GROMACS gmx rmsf tool.
Root-mean-square deviation
To calculate the root-mean-square deviation (RMSD) of the backbone atoms of GlyT2, for each sys-
tem the protein was fit to the first frame of the unrestrained 100 ns trajectory, and the deviation of
the backbone was calculated using the GROMACS gmx rms tool.
Pairwise distances
All pairwise distances were calculated using the GROMACS gmx distance tool. For the pairwise dis-
tance measurements between Y550 and the acyl-amino acids, C3 and Ca were chosen as the respec-
tive reference groups. The distance between the centres of mass was calculated for W563 and R439.
The mean distance and standard deviation for each system is given in Figures 3c and 4f.
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